Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CRNX
CRNX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRNX News
Crinetics Pharmaceuticals Q1 2026 Earnings Call Highlights
2d ago
seekingalpha
Crinetics Pharmaceuticals: Stock Potential Analysis
May 02 2026
Yahoo Finance
Latest Developments in the Biotech Sector
Apr 30 2026
NASDAQ.COM
Crinetics' PALSONIFY Receives EU Approval for Acromegaly Treatment
Apr 28 2026
NASDAQ.COM
PALSONIFY Approved in EU for Acromegaly Treatment
Apr 27 2026
Newsfilter
Neutrolis Appoints New Chief Business & Strategy Officer
Apr 15 2026
Globenewswire
Neutrolis Appoints New Chief Business Officer
Apr 15 2026
Newsfilter
Crinetics (CRNX.US) Officer Plans to Sell $3.27 Million in Common Stock via Form 144
Apr 08 2026
moomoo
Crinetics Pharmaceuticals Director Sells Shares
Mar 28 2026
NASDAQ.COM
Crinetics Pharmaceuticals Director Sells 5,000 Shares
Mar 28 2026
Fool
Crinetics Pharmaceuticals COO Resignation and Future Plans
Mar 23 2026
seekingalpha
Crinetics Pharmaceuticals Q4 2025 Earnings Call Highlights
Feb 27 2026
seekingalpha
Analyst Target Prices Indicate Potential for Pharmaceuticals ETF
Jan 29 2026
NASDAQ.COM
Crinetics Prices 7.62M Share Offering at $45.95, Raising $350M
Jan 07 2026
Globenewswire
Crinetics Pharmaceuticals Reports Significant Results in CAH Study with Atumelnant
Jan 05 2026
Benzinga
Crinetics Pharmaceuticals Updates on Atumelnant Phase 2 Trial Results and PALSONIFY Commercialization
Jan 05 2026
NASDAQ.COM
Show More News
